TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00678886

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: otelixizumab infusion plus physician determined standard of care
Description: infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion plus physician determined standard of care
Description: infusion
Study: NCT03797599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 minute audio book
Description: 5 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything') per session, for four sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20 minute audio book
Description: 20 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 25 minute audio book
Description: 25 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
Study: NCT01236599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene for thermoregulation in the preterm infant
Description: 3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene for thermoregulation in the preterm infant
Description: 3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Polyethylene for thermoregulation in the preterm infant
Description: 3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
Study: NCT03751488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010
Description: Single Dose of LY03010 at 351 mg or 156 mg or 117mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010
Description: Single Dose of LY03010 at 351 mg or 156 mg or 117mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03010
Description: Single Dose of LY03010 at 351 mg or 156 mg or 117mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Invega Sustenna 156 MG in 1 ML Prefilled Syringe
Description: Single Dose at 156mg
Study: NCT01286298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser gingivectomy
Description: Gingivectomy by diode laser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser gingivectomy
Description: Diode laser gingivectomy for gingival enlargement
Study: NCT00691015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT00912496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
Study: NCT03833440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monalizumab (IPH2201)
Description: 1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab (MEDI9447)
Description: 3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day
Study: NCT00691015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation (TBI)
Description: Given once or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin IV
Description: Given IV
Study: NCT00646009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol
Study: NCT04673162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone, Placebo
Description: iv administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone, Placebo
Description: iv administration
Study: NCT02161367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: Pharmacological category: antiflatulent~160mg Simethicone orally, 4 times a day for the first five postoperative days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Suspending Vehicle
Description: ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days
Study: NCT02381288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-448 Placebo
Description: TAK-448 placebo-matching solution for subcutaneous injection
Study: NCT03940404

Intervention type: DRUG
Intervention: Anlotinib Hydrochloride
Description: Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
Study: NCT00869674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GeneSearch™ Breast Lymph Node (BLN) Assay
Description: Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing.
Study: NCT02139228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-CRM197
Description: No vaccine administered in V37_07E2 study

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib-TT
Description: No vaccine administered in V37_07E2 study
Study: NCT02726204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gravity Elimination Alone
Description: CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
Study: NCT05182138

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unfortified potato plus placebo
Description: Volunteers will be given 300g of zinc unfortified cooked potato as well as a placebo every day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Biofortified potato plus placebo
Description: Volunteers will be given 300g of cooked potato biofortified with zinc and a placebo every day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unfortified potato plus zinc supplement
Description: Volunteers will be given 300g of zinc unfortified cooked potato and a zinc supplement containing 18mg of zinc, every day.
Study: NCT03269383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
Study: NCT04512404

Intervention type: DRUG
Intervention: HMG-CoA Reductase Inhibitor
Study: NCT04812691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10\^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.
Study: NCT01468012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa carbidopa and entacapone (LCE)
Description: 400mg/100mg/200mg, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo for LCE condition dosed twice daily
Study: NCT04082312

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00713050

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imitate Therapy
Description: Imitation-based computer therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imitate Therapy
Description: Imitation-based computer therapy
Study: NCT04324073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: (an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1
Study: NCT02198274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBH 1
Description: 100 mg/week
Study: NCT01192854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: Clevudine flexible dosages of 30 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Adefovir flexible dosages of 10 mg/day
Study: NCT00325728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
Study: NCT01167894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
Study: NCT02726204

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Path Assistance Alone
Description: CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Path Assistance Alone
Description: CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Path Assistance and Gravity Elimination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Path Assistance and Gravity Elimination
Study: NCT02945943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Velocity Low Amplitude mobilization
Description: Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
Study: NCT01712581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Study: NCT00652314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombi-Gel
Description: Applicaton of Hemostatic product during surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombi-Gel
Description: Applicaton of Hemostatic product during surgery
Study: NCT04052750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS follow-up
Description: In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
Study: NCT02945943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Protocol
Description: This exercise regimen is a modified version of the balance training program described by McKeon et al.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Protocol
Description: This exercise regimen is a modified version of the balance training program described by McKeon et al.
Study: NCT01722214

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
Study: NCT01855867

Intervention type: DRUG
Group type: OTHER
Intervention: Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Study: NCT02525809

Intervention type: DEVICE
Group type: OTHER
Intervention: Novae E®

Intervention type: DEVICE
Group type: OTHER
Intervention: Sunfit®

Intervention type: DEVICE
Group type: OTHER
Intervention: Quartz®
Study: NCT02573012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to prednisone
Description: Participants will receive placebo matched to prednisone orally for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to prednisone
Description: Participants will receive placebo matched to prednisone orally for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
Study: NCT00113555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACT (Adjustable Continence Therapy)
Description: surgically implanted device
Study: NCT02934061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tizaspray® administered intranasally
Description: 0,5 mg Tizaspray® administered intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirdalud® 2 mg tablets administered
Description: Sirdalud® 2 mg tablets administered in patients with acute low back pain
Study: NCT01518673

Intervention type: PROCEDURE
Intervention: Blood test
Description: Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
Study: NCT02325089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Description: Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
Study: NCT01922466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bee Venom Acupuncture
Description: Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~* 1st week - SC 0.2cc/day, 2 days/week~* 2nd week - SC 0.4cc/day, 2 days/week~* 3nd week - SC 0.8cc/day, 2 days/week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bee Venom Acupuncture
Description: Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~* 1st week - SC 0.2cc/day, 2 days/week~* 2nd week - SC 0.4cc/day, 2 days/week~* 3nd week - SC 0.8cc/day, 2 days/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxoprofen
Description: 60 mg/Tab, pers os 1Tab tid, for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxoprofen
Description: 60 mg/Tab, pers os 1Tab tid, for 3 weeks
Study: NCT01376505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2 vaccine
Description: Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
Study: NCT03833440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib (AZD6738)
Description: 240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOCETAXEL
Description: 75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: 600 mg QD~1 cycle = 28 days
Study: NCT01228669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0172-0000-2021
Description: Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0172-0000-2021
Description: Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
Study: NCT04657120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: YEARS algorithm
Description: Patients randomized to the YEARS algorithm will be evaluated according to the YEARS algorithm consisting of three items of the original Wells rule (clinical signs of DVT, haemoptysis and 'PE most likely diagnosis') and a D-dimer test. In patients without any of the three items and a D-dimer level \<1.0 μg/mL (\<1000ng/mL), and in patients with ≥1 items and a D-dimer level \<0.5 μg/mL (\<500 ng/mL) a PE is excluded without CTPA. In the other patients a standard contrast enhanced CTPA will be performed according to local practice. PE is defined as at least one filling defect in the pulmonary artery tree on CTPA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTPA
Description: Patients randomized to the CTPA management group will undergo a contrast enhanced CTPA to rule out PE according to standard local practice.
Study: NCT04166916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic stimulation
Description: Acoustic stimulation to modulate slow waves.
Study: NCT01376505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extension HER-2 vaccine trial at OBD
Description: Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
Study: NCT02692560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-STAND
Description: Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: Participants receive enhanced usual care based on general healthy living topics that are available to all Kaiser Permanente Washington enrollees.